Exploring New Paths for CAR T-Cell Therapy Research in Multiple Myeloma
Melissa Alsina, MD, gave a talk on novel CAR therapies, targets, and approaches at the 2022 ASCO meeting.
CAR T-Cell Therapy Directed at CLDN18.2 Effective in Gastric, Pancreatic Adenocarcinoma
Findings from the US-based study align with results from a phase 1b/2 study completed in China of CT041 in patients with gastric and gastroesophageal junction adenocarcinoma.
Kim A. Reiss Binder, MD, on the Potential of CAR Macrophages in Solid Tumors
The assistant professor of medicine at University of Pennsylvania Hospital stressed the importance of tumor sequencing.
POLARIS: OriCAR-017 Elicits 100% ORR in Patients With Relapsed/Refractory Multiple Myeloma
The phase 1, open-label, single-arm study demonstrated favorable safety and robust efficacy for the autologous GPRC5D-directed CAR-T cell therapy.
BCMA/CD19 Dual-Targeting CAR-T GC012F Continues to Display Durable Response for RRMM in Updated Results
Data were presented at ASCO 2021 and EHA 2021 for the initial 19 patients. Now, investigators are painting a fuller picture with an additional 9.
Novel Healthy Cell Sparing CAR T-cell Therapy Enters Clinical Studies for Solid Tumors
The BASECAMP-1 study is currently enrolling participants to explore the feasibility of manufacturing a novel CAR T-cell therapy with a target antigen activator and a HLA LOH-based blocker.
TCR Therapy Shows Anti-Tumor Activity in MRCLS
Higher-dose lymphodepleting regimens led to higher toxicity but high response rates.
Cilta-Cel Shows Promise in Earlier Lines of Treatment in Patients With Progressive Multiple Myeloma
Cohort A of the CARTITUDE-2 study is evaluating cilta-cel safety and efficacy in patients with multiple myeloma who received 1 to 3 prior lines of therapy.
Lete-Cel Exhibits Anti-Tumor Activity, Long Median PFS in Patients With Myxoid/Round Cell Liposarcoma
“Therapy was found to be safe and tolerable. This initial data formed the basis for further exploration that is currently ongoing in the IGNYTE-ESO study,” investigator Sandra P. D’Angelo, MD, tells CGTL.
Brexu-Cel Shows Efficacy in Mantle Cell Lymphoma in Real-World Setting
High response rates were seen in patients that would not meet ZUMA-2 eligibility criteria.
Axi-Cel Shows Favorable Outcomes in Large B-Cell Lymphoma Regardless of Race, Ethnicity
No differences were found in overall survival and progression free survival across races.
Allogeneic CAR T-Cell Therapy Well-Tolerated and Effective Across B-Cell Malignancies
A recent meta-analysis reviewed data across 146 patients in 9 clinical trials.
CAR T-Cell Therapy Yields High Response Rates in B-NHL
Relma-cel was previously approved in China in September 2021 for the treatment of B-cell non-Hodgkin lymphoma.
NK Cell Therapy Avelumab Combo Well Tolerated With Some Clinical Activity in Sarcoma
A phase 1 trial evaluated the combination in patients regardless of PD-L1 status and no differences were seen between those negative or positive.
Tim Miller, PhD, on Supporting Gene Therapy Development
The cofounder, president, and chief executive officer of Forge Biologics discussed the company’s approach to gene therapy manufacturing.
Donald Kohn, MD, on the Trajectory of Gene Therapy
The renowned professor from University of California Los Angeles reflected on receiving the Outstanding Achievement Award from the ASGCT.
Liso-Cel Yields High Response Rates and Positive PROs in LBCL
Treated patients had significant improvements in fatigue and lymphoma symptoms.
Lentiviral Cell Therapy Normalizes Hemoglobin in Pyruvate Kinase Deficiency
RP-L301 also improved hemolysis and eliminated the need for red blood cell transfusions for up to 1year after therapy.
Developing Safer Viral Vectors for Gene Therapy
The chief executive officer of Ring Therapeutics, Tuyen Ong, MD, discussed the potential of anellovirus vectors for use in gene therapy.
Amy Pooler, PhD, on Improving Gene Delivery to the CNS
The vice president of neuroscience at Sangamo Therapeutics discussed identifying novel capsids with improved neuronal transduction to the CNS.
Jason Fontenot, PhD, on Reducing the Need for Immunosuppression in Renal Transplantation
The chief scientific officer of Sangamo Therapeutics discussed the first-in-human STEADFAST trial.
Gene Therapy May Eliminate Need for ERT in Late-Onset Pompe Disease
All study participants met criteria to remain off enzyme replacement therapy through 104 weeks after treatment.
Andras Heczey, MD, on Antitumor Activity of CAR NKTs in Solid Tumors
The director of the Liver Tumor Program at Texas Children’s Hospital discussed a phase 1 study of CAR NK T-cells in neuroblastoma.
Cell Therapy Modulates Tumor Microenvironment in Glioblastoma
The cell therapy was tolerated although there was a SUSAR of GGT elevations.
Carsten Bönnemann, MD, on Identifying At-Risk Genotypes for DMD Gene Therapy
The senior investigator from NINDS discussed findings investigating serious AEs across different trials.
Ami J. Shah, MD, on Reaching Normalized Hemoglobin With Gene-Edited Cell Therapy in PKD
The clinical professor of pediatrics at Stanford Medicine discussed positive interim findings from a phase 1 study of RP-L301.
Gene Therapy for LAD-I Posts Impressive Survival Data
In an interview with CGTLive, study primary investigator Donald Kohn, MD, discussed the safety and efficacy observed in the phase 2 trial.
CGTLive’s Weekly Rewind – May 20, 2022
Review top news and interview highlights from the week ending May 20, 2022.
Florian Eichler, MD, on Promising Efficacy of AXO-AAV-GM2 in GM2 Gangliosidosis
The director of the leukodystrophy service at Mass Gen discussed progress dosing in the phase 1/2 trial.
DMD Gene Therapy Shows Continued Microdystrophin Expression
Motor and pulmonary function have stabilized or improved in participants treated with SGT-001.
